Abstract
GRAIL, Inc. will report financial results on November 4, 2026 Post-Mkt, and this preview outlines consensus projections for revenue and EPS, reviews last quarter’s performance, details segment mix, and highlights the near-term catalysts investors are watching.
Market Forecast
Street models for the current quarter point to revenue of 44.35 million US dollars, up 25.27% year over year, with adjusted EPS expected at -2.60, implying a 26.05% year-over-year improvement; EBIT is projected at a loss of 133.90 million US dollars, with a 2.32% year-over-year deterioration. Forecasts for gross margin and net margin have not been communicated in the latest models.
The main business remains concentrated in Screening, and near-term demand is expected to be framed by physician adoption, diagnostic ordering behaviors, and label discussions following recent regulatory milestones. The most promising segment is Screening (Galleri), which generated 42.64 million US dollars in the last quarter; consensus implies that the company’s year-over-year growth of about 25.27% this quarter will be driven primarily by this segment.
Last Quarter Review
In the last reported quarter, GRAIL, Inc. delivered revenue of 44.69 million US dollars (+25.72% year over year), gross profit margin of 46.78%, a GAAP net loss attributable to stockholders of 110.00 million US dollars (net margin -246.71%), and adjusted EPS of -2.56 (a 19.50% year-over-year improvement).
Revenue exceeded consensus by 1.93 million US dollars and adjusted EPS beat by 0.09, while EBIT was a loss of 173.78 million US dollars; the company sustained a high gross margin profile even as operating losses remained elevated.
Screening contributed 42.64 million US dollars (95.42% of sales) and Development Services contributed 2.05 million US dollars (4.58% of sales); company-level revenue expanded 25.72% year over year, underscoring robust demand relative to the prior year.
Current Quarter Outlook
Screening revenue trajectory and margin mix
Screening is expected to remain the core revenue engine, with underlying demand tied to physician ordering and follow-through from enterprise channels. With Screening accounting for 95.42% of last quarter’s revenue, consolidated growth in the models implies that incremental volume and price realization within Galleri will be the dominant contributors in the current quarter. Management has not provided a gross margin outlook for this quarter, but last quarter’s 46.78% level provides a useful anchor as investors assess whether volume leverage, test mix, and processing efficiency can sustain margin resilience against inflationary inputs and logistics expenses.
Engagement after the positive advisory panel vote has the potential to shape the cadence of orders as clinicians calibrate their workflows around test positioning and follow-up pathways. In the absence of formal payer-wide coverage shifts this quarter, consolidated growth is likely to reflect volume expansion within existing pay channels and self-pay demand. Watch the conversion of physician education initiatives into steady-state ordering patterns, as that will influence both top-line stability and the company’s ability to optimize cost per test and strengthen the gross margin trajectory.
A key question for this print is whether Screening revenue can hold near last quarter’s absolute level while also delivering year-over-year growth aligned with consensus. Operationally, signals investors will look for include sample volume trends, turnaround time consistency, and the balance of direct-to-physician versus channel partner pipelines—each shaping realized pricing, promotional intensity, and cost absorption across the lab footprint.
Regulatory catalysts shaping the most promising segment
The positive US advisory committee vote on September 23, 2026 (safety 10–0, efficacy 6–4, benefit-risk 7–2) has become an important reference point for clinician confidence and internal commercial planning. Label scope and post-market evidence expectations will ultimately shape the breadth of the clinical use-case and could inform payer discussions over the next several quarters; while no formal approval decision is expected this quarter, the panel outcome is already influencing sentiment and the pace of dialogues with stakeholders.
Evidence generation remains central to commercial momentum: across large-scale cohorts, reported performance and safety data have been supportive, reinforcing that Galleri complements standard screening with improved detection in earlier stages in prospective studies. The near-term revenue impact is driven less by new regulatory decisions and more by the operational harnessing of this momentum—physician outreach, adherence to recommended patient selection, and consistency in follow-up pathways.
From a medium-term perspective, analysts widely frame Screening as the company’s most promising growth vector given its scale and addressable demand once labeling and coverage frameworks stabilize. In the current quarter, however, the financial effect is likely to manifest primarily through steady expansion within current channels rather than step-change shifts, meaning investors should look for incremental progress updates rather than binary catalysts in the print.
What will drive the stock this quarter
The stock’s near-term reaction will likely hinge on four items: revenue trajectory versus the 44.35 million US dollars consensus, any commentary around gross margin durability relative to last quarter’s 46.78%, operating expense discipline relative to EBIT loss expectations, and qualitative updates on regulatory and payer interactions. A modest top-line beat coupled with stable or improving unit economics would help reinforce the pathway to narrowing losses, even if EBIT remains negative in absolute terms. Conversely, any shortfall on volumes or mix would raise questions about the elasticity of demand and the effectiveness of ongoing educational and commercial initiatives.
Updates tied to evidence readouts and real-world usage metrics will be scrutinized for their implications on physician adoption curves. Commentary on the labeling path and any pilot reimbursement arrangements could inform the slope of the revenue ramp in 2027 and beyond, and could influence how the market interprets the durability of this quarter’s growth. Investors will also search for signals on operating leverage: improved throughput, automation in lab operations, and procurement efficiencies, all of which can bend the cost curve alongside revenue growth.
Finally, the narrative around follow-up care coordination and false-positive management remains important for confidence; practical clarity on patient pathways and provider burden can reduce friction in ordering behavior. Against that backdrop, maintaining consistent turnaround times and minimizing administrative overhead for clinicians are operational factors that can produce incremental upside by sustaining repeat ordering and reducing drop-off in the funnel. In short, the more this quarter’s update demonstrates steady execution and crisp conversion from interest to orders, the more support the stock may find in the near term.
Analyst Opinions
Recent opinions skew clearly bullish, with multiple high-profile institutions reiterating or initiating Buy ratings and no recent Sell ratings in the surveyed window; within the set of directional calls captured, the bullish-to-bearish ratio trends decisively toward bullish given the absence of Sells.
UBS reaffirmed its positive stance and lifted its price target to 175.00 US dollars, citing the supportive US advisory committee vote and the potential for regulatory progress to catalyze broader adoption over time; the firm frames the risk-reward as favorable if the company executes on commercialization and maintains evidence momentum. Canaccord Genuity’s Kyle Mikson reiterated a Buy rating and raised his target to 150.00 US dollars in a separate note, emphasizing that near-term sales should benefit from strengthening physician engagement, while medium-term catalysts hinge on labeling clarity and payer dialogue.
The bullish camp centers on three arguments for the upcoming quarter. First, consensus implies roughly 25% year-over-year revenue growth, a cadence that, if met or modestly exceeded, can validate the durability of demand following the advisory committee milestone. Second, the gross margin backdrop—anchored by last quarter’s 46.78%—creates room for upside if mix and operational efficiency deliver incremental leverage, even if EBIT remains negative. Third, clinical and real-world evidence continues to accumulate in favor of consistent performance and safety, which supports physician confidence and could accelerate adoption pathways once labeling is finalized.
Bulls also outline tangible checkpoints to evaluate execution in this print: sample volumes, order growth per active account, and the trajectory of repeat ordering by clinicians who have already integrated testing into their workflows. They note that beat-and-raise dynamics may emerge if cost containment combines with stable mix, particularly as the company consolidates efficiency gains within its lab operations. While the structural path to profitability requires scale, the majority view holds that consistent high-20s year-over-year growth alongside disciplined operating spend can meaningfully narrow losses and preserve cash runway, bridging to the next set of regulatory and payer milestones.
Overall, the majority perspective anticipates a consolidated update that reinforces the investment case: revenue around 44.35 million US dollars with year-over-year growth near 25.27%, adjusted EPS near -2.60 with an improving year-over-year delta, and qualitative commentary that strengthens confidence in the medium-term trajectory for Screening. Should GRAIL, Inc. deliver clean execution and constructive commentary, the bullish view expects sentiment to remain supported into subsequent catalysts.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments